Gold prices set for weekly drop as strong dollar weighs; Trump tariffs in focus
BOSTON - NeuroNOS, a subsidiary of Beyond Air (NASDAQ:XAIR), has made a significant breakthrough in Alzheimer’s disease (AD) research, as detailed in a recent publication in the peer-reviewed journal Translational Psychiatry. The study, led by NeuroNOS’s Chief Scientific Officer Prof. Haitham Amal, unveils a novel mechanism in the early stages of Alzheimer’s disease, potentially paving the way for new therapeutic strategies.
Alzheimer’s disease affects over 55 million people worldwide and incurs an economic burden exceeding $1 trillion annually. Despite extensive research, effective treatments to halt or reverse the progression of AD have remained elusive. Prof. Amal’s research indicates that disruptions in nitric oxide (NO)-related pathways, especially S-nitrosylation, may play a crucial role in the disease’s onset. The study found consistent molecular changes in two established AD mouse models, suggesting that targeting NO production could be a promising approach to treating early-stage Alzheimer’s.
NeuroNOS CEO Amir Avniel highlighted the company’s rapid progress from concept to reality, emphasizing the potential impact on the brain disease therapeutic landscape. The company has filed patents for its innovative approach and is collaborating with international partners to produce pharmaceutical ingredients and formulations. With plans to initiate clinical trials for autism in the United States in 2026, NeuroNOS is advancing its drug development platform, which has already shown promise in preclinical studies for autism and glioblastoma.
The research builds on NeuroNOS’s discovery of a link between autism and Alzheimer’s disease, involving impairment of the neuronal nitric oxide synthase enzyme, which regulates NO in the brain. This finding supports the company’s strategy to target NO pathways for multiple neurological conditions. The company’s scientific team, which includes Nobel laureates and autism experts, collaborates with the Hebrew University of Jerusalem and its School of Pharmacy.
The global market for brain therapeutics is expanding, driven by an aging population and the increasing prevalence of neurological disorders. NeuroNOS’s focus on modulating NO levels in the brain places it at the forefront of addressing unmet medical needs in this field. With impressive revenue growth of 339% in the last twelve months and a strong current ratio of 3.56, the company maintains solid liquidity to fund its development programs. InvestingPro offers additional valuable insights through its 10+ ProTips and extensive financial metrics, helping investors make informed decisions in the dynamic biotech sector. The company aims to translate its preclinical findings into effective therapies for complex brain diseases.
This news is based on a press release statement and reflects the ongoing efforts and potential advancements in the treatment of neurological disorders by NeuroNOS and Beyond Air.
In other recent news, Beyond Air reported a notable revenue increase for the third fiscal quarter of 2025, reaching $1.1 million, which marks a 175% year-over-year growth. The company also announced a narrowing net loss, with earnings per share improving to $0.15 from $0.50 per share last year. Beyond Air has expanded its international presence with new distribution agreements for its LungFit PH system in several countries, including France, Turkey, Romania, and Morocco. The company has also initiated an at-the-market equity offering, potentially raising up to $35 million, as per a recent SEC filing. BTIG reiterated a Neutral rating for Beyond Air, acknowledging the revenue beat but maintaining a cautious outlook. Beyond Air highlighted the signing of new hospital contracts and the renewal of existing ones, projecting continued revenue growth. The company concluded the quarter with $10.9 million in cash and equivalents, asserting that its cash reserves are sufficient to fund operations through the spring of 2026. Additionally, Beyond Air is advancing its LungFit PH system internationally, expecting a substantial impact on revenue in the latter half of fiscal year 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.